SLC29A1 and familial pancreatic carcinoma: Its advantages in overcoming drug resistance are: 1) Oral formulations are delivered through albumin binding or nanocarriers to avoid insufficient uptake caused by low hENT1 expression (D et al., 2025), and in pancreatic cancer models, the efficacy is 30% higher than that of intravenous formulations.